A Phase 1b/2 Study of Ramucirumab in Combination With LY2875358 in Patients With Advanced Cancer
Latest Information Update: 21 Dec 2020
At a glance
- Drugs Emibetuzumab (Primary) ; Ramucirumab
- Indications Adenocarcinoma; Gastric cancer; Liver cancer; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Eli Lilly and Company
- 29 May 2019 Safety and efficacy results published in the Clinical Cancer Research.
- 28 Mar 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.